CAR T-Cell Therapy for Leukemia

Adult CAR T-Cell Therapy


Pediatric CAR T-Cell Therapy


Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH® to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Leukemia nurse practitioner Ilene Galinsky and physician Daniel DeAngelo


CAR T-cell therapy is a promising treatment for patients with many types of blood cancer, including leukemia. It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer.

Learn more about CAR T-cell therapy.

CAR T-cell therapy is FDA-approved for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Patients are evaluated carefully to determine if this therapy is appropriate for them, and are cared for by a team experienced in CAR T-cell therapy.

In addition to the FDA-approved therapy, Dana-Farber Brigham Cancer Center also offers clinical trials evaluating CAR T-cell therapy for other types of leukemia, as well as other blood cancers.

Key Eligibility Criteria for CAR T-Cell Therapy for Leukemia

Key eligibility criteria include:

  • Confirmed diagnosis of B-cell acute lymphoblastic leukemia (ALL) that has either not responded or has relapsed after one line of prior treatment.
  • Adequate organ, cardiac, and pulmonary function (must meet established criteria/measures).

Children and young adults may also be evaluated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center (Dana-Farber/Boston Children's).